Method for use in cataract surgery

• US 20020165522A1
• Filed: 05/03/2001
• Published: 11/07/2002
• Est. Priority Date: 05/03/2001
• Status: Active Grant

• Current Assignee: Johnson & Johnson Surgical Vision, Inc. (Johnson & Johnson)
• Original Assignee: Jorgen Holmen
• Inventors: Holmen, Jorgen
• Granted Patent: US 6,533,769 B2
• Time in Patent Office: Days
• US Class Current: 604/521
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61F 9/00745 using mechanical vibrations, e.g. ultrasonic
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/12 for cataracts

Abstract

A method for treatment of residual lens epithelial cells is disclosed. The method provides increased safety during local treatment in ocular surgery by improved administration of active agents. The method is particularly useful in treatment of proliferative events in ocular surgery, such as posterior capsular opacification.

Claims

1. A method of preventing posterior capsule opacification (PCO) from occurring after cataract surgery, comprising the steps of:

filling the anterior chamber (5) of an eye with a viscoelastic solution (13), to maintain the depth of the anterior chamber (5) and to prevent gas (14) from leaking out from the lens capsule (8),

expanding the lens capsule (8) and keep it expanded, and injecting an active agent (14;

15), toxic to lens epithelial cells, into the lens capsule (8).

2. The method according to claim 1, wherein the expansion of the lens capsule (8) is accomplished with a gas (14).

3. The method according to claim 2, wherein the gas (14) is the active agent.

4. The method according to claim 1, wherein said active agent (15) is injected in form of a solution onto the inner surface of the air-filled lens capsule (8),

5. The method according to claim 4, wherein the active agent (15) is a colored active agent.

6. The method according to claim 4, wherein the active agent (15) is an active agent to which a dye has been bound.

7. The method according to claim 4, wherein the active agent (15) is in a colored solution.

8. The method according to claim 1, wherein the active agent (15), after having (irreversibly) damaged or killed the lens epithelial cells (9), is inactivated in or removed from the lens capsule (8).

9. The method according to claim 1, comprising the step of coating the inner surface of the air-filled lens capsule (11) with a second active agent, capable of preventing cell growth and migration onto the posterior region of the capsule for as long as possible.

10. The method according to claim 9, wherein the addition of the second active agent is subsequent to the addition of the first active agent.

11. The method according to claim 9, wherein both the first and second active agents are administered at the same time.

12. The method according to claim 9, wherein an active agent is administered which have the properties of both the first and the second agent active.

13. The method according to claim 1, wherein the viscoelastic solution (13) has the ability to eliminate the toxicity of the active agents.

14. The method according to claim 1, wherein the viscoelastic solution (13) has the ability to prevent diffusion of the active agents to adjacent tissues.

15. The method of according to claim 1, comprising implanting an intraocular lens, filling the anterior chamber (5), expanding the lens capsule (8) and keep it expanded and injecting an active agent (14;

15) into the lens capsule (8).

17. The method according to claim 16, wherein the expansion of the lens capsule (8) is accomplished with a gas (14).

18. The method according to claim 17, wherein the gas (14) is the active agent.

19. The method according to claim 16, wherein said active agent (15) is injected in form of a solution onto the inner surface of the air-filled lens capsule (8)

20. The method according to claim 19, wherein the active agent (15) is a colored active agent.

21. The method according to claim 19, wherein the active agent (15) is an active agent to which a dye has been bound.

22. The method according to claim 19, wherein the active agent (15) is in a colored solution.

23. The method according to claim 16, wherein the active agent (15), after having (irreversibly) damaged or killed the lens epithelial cells (9), is inactivated in or removed from the lens capsule (8).

24. The method according to claim 16, comprising the step of coating the inner surface of the air-filled lens capsule (11) with a second active agent, capable of preventing cell growth and migration onto the posterior region of the capsule for as long as possible.

25. The method according to claim 24, wherein the addition of the second active agent is subsequent to the addition of the first active agent.

26. The method according to claim 24, wherein both the first and second active agents are administered at the same time.

27. The method according to claim 24, wherein an active agent is administered which have the properties of both the first and the second agent active.

28. The method according to claim 16, wherein the viscoelastic solution (13) has the ability to eliminate the toxicity of the active agents.

29. The method according to claim 16, wherein the viscoelastic solution (13) has the ability to prevent diffusion of the active agents to adjacent tissues.

16. A method of administration of substances active against lens epithelial cells, comprising the steps of:

filling the anterior chamber (5) of an eye with a viscoelastic solution (13), to maintain the depth of the anterior chamber (5) and to prevent gas (14) from leaking out from the lens capsule (8),

expanding the lens capsule (8) and keep it expanded, and injecting an active agent (14;

15), toxic to lens epithelial cells, into the lens capsule (8).